{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:53:32Z","timestamp":1791928412028,"version":"4.3.4"},"reference-count":149,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes mellitus (T2DM) are closely linked conditions that share common disturbances in metabolism, inflammation, and fibrotic processes. MASH is characterized by fat accumulation in the liver, hepatocyte damage, and progressive fibrosis, whereas T2DM involves insulin resistance and impaired beta-cell function. The coexistence of these disorders creates a liver and pancreas feedback loop, in which impaired hepatic insulin signaling worsens blood glucose control and high glucose levels further damage the liver. Key cellular contributors include hepatocytes, Kupffer cells, hepatic stellate cells, and pancreatic \u03b2-cells, while non-coding RNAs influence lipid metabolism and inflammation. Emerging therapies, including GLP1 receptor agonists, dual incretin agents, PPAR modulators, thyroid hormone receptor beta modulators, FXR agonists, and FGF analogues, along with lifestyle interventions, show promise in improving both liver and metabolic outcomes. Precision medicine approaches may further refine individualized treatment strategies.<\/jats:p>","DOI":"10.3389\/fendo.2025.1753393","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T05:28:09Z","timestamp":1768800489000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Synergistic therapeutic strategies for metabolic dysfunction-associated steatohepatitis and type 2 diabetes mellitus: molecular insights and clinical advances"],"prefix":"10.3389","volume":"16","author":[{"given":"Bo","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.742382","article-title":"Non-alcoholic steatohepatitis pathogenesis, diagnosis, and treatment","volume":"8","author":"Zhu","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.19615","article-title":"Metabolic dysfunction-associated steatotic liver disease in adults: A review","author":"Tilg","year":"2025","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2412865","article-title":"Metabolic dysfunction-associated steatotic liver disease","volume":"393","author":"Targher","year":"2025","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"101320","DOI":"10.1016\/j.lanepe.2025.101320","article-title":"A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis","volume":"54","author":"Lazarus","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"107249","DOI":"10.1016\/j.vph.2023.107249","article-title":"Two sides of the same coin: Non-alcoholic fatty liver disease and atherosclerosis","volume":"154","author":"Zhu","year":"2024","journal-title":"Vascul Pharmacol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-024-01951-9","article-title":"Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy","volume":"9","author":"Lu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"8731","DOI":"10.3390\/ijms25168731","article-title":"Pathophysiological relationship between type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: novel therapeutic approaches","volume":"25","author":"Ferdous","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00318-8","article-title":"Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment","volume":"13","author":"Stefan","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e186420","DOI":"10.1172\/JCI186420","article-title":"MASH: the nexus of metabolism, inflammation, and fibrosis","volume":"135","author":"Steinberg","year":"2025","journal-title":"J Clin Invest"},{"key":"B12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1210\/er.2012-1009","article-title":"Diabetes and nonalcoholic Fatty liver disease: a pathogenic duo","volume":"34","author":"Williams","year":"2013","journal-title":"Endocr Rev"},{"key":"B13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nature13478","article-title":"The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes","volume":"510","author":"Perry","year":"2014","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1193373","article-title":"Uncoupling hepatic insulin resistance - hepatic inflammation to improve insulin sensitivity and to prevent impaired metabolism-associated fatty liver disease in type 2 diabetes","volume":"14","author":"Niranjan","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"103202","DOI":"10.1016\/j.ebiom.2020.103202","article-title":"A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis","volume":"63","author":"Pan","year":"2021","journal-title":"EBioMedicine"},{"key":"B16","doi-asserted-by":"publisher","first-page":"100065","DOI":"10.1016\/j.molpha.2025.100065","article-title":"The peroxisome proliferator-activated receptor alpha\/beta\/gamma agonist NCPC-626 from microbial metabolites alleviates metabolic dysfunction-associated steatohepatitis in mice","volume":"107","author":"Yu","year":"2025","journal-title":"Mol Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.034","article-title":"FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond","volume":"81","author":"Harrison","year":"2024","journal-title":"J Hepatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00404-2","article-title":"The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer","volume":"18","author":"Sun","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.06.010","article-title":"Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review","volume":"56","author":"Thoma","year":"2012","journal-title":"J Hepatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2013.00037","article-title":"Beta cell dysfunction and insulin resistance","volume":"4","author":"Cerf","year":"2013","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2337\/db23-0761","article-title":"Increased Genetic Risk for beta-Cell Failure Is Associated With beta-Cell Function Decline in People With Prediabetes","volume":"73","author":"Billings","year":"2024","journal-title":"Diabetes"},{"key":"B22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11886-016-0755-4","article-title":"Genetics of insulin resistance and the metabolic syndrome","volume":"18","author":"Brown","year":"2016","journal-title":"Curr Cardiol Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2044-5","article-title":"Genetic predisposition to obesity leads to increased risk of type 2 diabetes","volume":"54","author":"Li","year":"2011","journal-title":"Diabetologia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat Genet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24806","article-title":"Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents","volume":"55","author":"Santoro","year":"2012","journal-title":"Hepatology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of european descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/ng1732","article-title":"Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes","volume":"38","author":"Grant","year":"2006","journal-title":"Nat Genet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/79216","article-title":"The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes","volume":"26","author":"Altshuler","year":"2000","journal-title":"Nat Genet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nature05616","article-title":"A genome-wide association study identifies novel risk loci for type 2 diabetes","volume":"445","author":"Sladek","year":"2007","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032922","article-title":"Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes","volume":"350","author":"Gloyn","year":"2004","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/science.1141634","article-title":"A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity","volume":"316","author":"Frayling","year":"2007","journal-title":"Science"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-018-2860-6","article-title":"Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease","volume":"75","author":"Ipsen","year":"2018","journal-title":"Cell Mol Life Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.metabol.2014.04.003","article-title":"De novo lipogenesis in health and disease","volume":"63","author":"Ameer","year":"2014","journal-title":"Metabolism"},{"key":"B36","doi-asserted-by":"publisher","first-page":"101193","DOI":"10.1016\/j.xcrm.2023.101193","article-title":"Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice","volume":"4","author":"Desjardins","year":"2023","journal-title":"Cell Rep Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.cmet.2017.08.011","article-title":"Acetyl coA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: A bedside to bench investigation","volume":"26","author":"Kim","year":"2017","journal-title":"Cell Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30765","article-title":"Hepatocyte deletion of triglyceride-synthesis enzyme acyl coA: diacylglycerol acyltransferase 2 reduces steatosis without increasing inflammation or fibrosis in mice","volume":"70","author":"Gluchowski","year":"2019","journal-title":"Hepatology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"101703","DOI":"10.1016\/j.molmet.2023.101703","article-title":"Hepatic follistatin increases basal metabolic rate and attenuates diet-induced obesity during hepatic insulin resistance","volume":"71","author":"Tao","year":"2023","journal-title":"Mol Metab"},{"key":"B40","doi-asserted-by":"publisher","first-page":"11595","DOI":"10.1038\/s41467-025-66296-5","article-title":"Fructose and follistatin potentiate acute MASLD during complete hepatic insulin resistance","volume":"16","author":"Tao","year":"2025","journal-title":"Nat Commun"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3920196","DOI":"10.1155\/2020\/3920196","article-title":"The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD)","volume":"2020","author":"Tanase","year":"2020","journal-title":"J Diabetes Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"110515","DOI":"10.4239\/wjd.v16.i9.110515","article-title":"Macrophage and inflammation in diabetes and metabolic dysfunction-associated steatotic liver disease: From mechanisms to therapeutic strategies","volume":"16","author":"Zhang","year":"2025","journal-title":"World J Diabetes"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.708978","article-title":"Hepatic macrophage as a key player in fatty liver disease","volume":"12","author":"Xu","year":"2021","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2021.12.006","article-title":"Mechanisms of NLRP3 inflammasome-mediated hepatic stellate cell activation: Therapeutic potential for liver fibrosis","volume":"10","author":"Charan","year":"2023","journal-title":"Genes Dis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"101418","DOI":"10.1016\/j.jhepr.2025.101418","article-title":"C\/EBPbeta-VCAM1 axis in Kupffer cells promotes hepatic inflammation in MASLD","volume":"7","author":"Lin","year":"2025","journal-title":"JHEP Rep"},{"key":"B46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.immuni.2021.12.013","article-title":"Inflammation in obesity, diabetes, and related disorders","volume":"55","author":"Rohm","year":"2022","journal-title":"Immunity"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/cells9102258","article-title":"Kupffer cells sense free fatty acids and regulate hepatic lipid metabolism in high-fat diet and inflammation","volume":"9","author":"Diehl","year":"2020","journal-title":"Cells"},{"key":"B48","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.bpg.2011.02.005","article-title":"Mechanisms of hepatic fibrogenesis","volume":"25","author":"Lee","year":"2011","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.7150\/thno.106597","article-title":"Metabolism of hepatic stellate cells in chronic liver diseases: emerging molecular and therapeutic interventions","volume":"15","author":"Yan","year":"2025","journal-title":"Theranostics"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1649179","article-title":"The pivotal role of TGF-beta\/Smad pathway in fibrosis pathogenesis and treatment","volume":"15","author":"Chen","year":"2025","journal-title":"Front Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00462","article-title":"Targeting mechanotransduction at the transcriptional level: YAP and BRD4 are novel therapeutic targets for the reversal of liver fibrosis","volume":"7","author":"Zhubanchaliyev","year":"2016","journal-title":"Front Pharmacol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2025.05.023","article-title":"RXRalpha modulates hepatic stellate cell activation and liver fibrosis by targeting CaMKKbeta-AMPKalpha axis","volume":"15","author":"Cai","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"B53","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41467-024-55738-1","article-title":"Alleviation of liver fibrosis by inhibiting a non-canonical ATF4-regulated enhancer program in hepatic stellate cells","volume":"16","author":"Yang","year":"2025","journal-title":"Nat Commun"},{"key":"B54","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/jcp.22783","article-title":"PAI-1 in tissue fibrosis","volume":"227","author":"Ghosh","year":"2012","journal-title":"J Cell Physiol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3390\/antiox14010072","article-title":"Oxidative stress and cardiovascular complications in type 2 diabetes: from pathophysiology to lifestyle modifications","volume":"14","author":"Caturano","year":"2025","journal-title":"Antioxid (Basel)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.892672","article-title":"Contribution of liver and pancreatic islet crosstalk to beta-cell function\/dysfunction in the presence of fatty liver","volume":"13","author":"Lopez-Bermudo","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.2337\/dbi22-0002","article-title":"Cross talk between insulin and glucagon receptor signaling in the hepatocyte","volume":"71","author":"Habegger","year":"2022","journal-title":"Diabetes"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2024.04.006","article-title":"Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease","volume":"36","author":"Bo","year":"2024","journal-title":"Cell Metab"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e19192","DOI":"10.7717\/peerj.19192","article-title":"The role of endoplasmic reticulum stress in type 2 diabetes mellitus mechanisms and impact on islet function","volume":"13","author":"He","year":"2025","journal-title":"PeerJ"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1663353","article-title":"The endocrine role of hepatokines: implications for human health and disease","volume":"16","author":"Iglesias","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.01.006","article-title":"The role of hepatokines in NAFLD","volume":"35","author":"Stefan","year":"2023","journal-title":"Cell Metab"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0048-0","article-title":"Inactivating hepatic follistatin alleviates hyperglycemia","volume":"24","author":"Tao","year":"2018","journal-title":"Nat Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2010.09.015","article-title":"A liver-derived secretory protein, selenoprotein P, causes insulin resistance","volume":"12","author":"Misu","year":"2010","journal-title":"Cell Metab"},{"key":"B64","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41392-022-01073-0","article-title":"Trends in insulin resistance: insights into mechanisms and therapeutic strategy","volume":"7","author":"Li","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1205951109","article-title":"Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor beta-Klotho","volume":"109","author":"Fu","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.09.008","article-title":"Macrophage miR-34a is a key regulator of cholesterol efflux and atherosclerosis","volume":"28","author":"Xu","year":"2020","journal-title":"Mol Ther"},{"key":"B67","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1530\/EJE-14-0867","article-title":"Elevated circulating microRNA-122 is associated with obesity and insulin resistance in young adults","volume":"172","author":"Wang","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1172\/JCI63966","article-title":"miR-122 regulates hepatic lipid metabolism and tumor suppression","volume":"122","author":"Wen","year":"2012","journal-title":"J Clin Invest"},{"key":"B69","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1038\/s41467-022-31317-0","article-title":"MicroRNA-21 promotes pancreatic beta cell function through modulating glucose uptake","volume":"13","author":"Liu","year":"2022","journal-title":"Nat Commun"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2013.03.014","article-title":"MicroRNA-21 activates hepatic stellate cells via PTEN\/Akt signaling","volume":"67","author":"Wei","year":"2013","journal-title":"BioMed Pharmacother"},{"key":"B71","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.trsl.2018.09.006","article-title":"Circulating miR-143-3p inhibition protects against insulin resistance in Metabolic Syndrome via targeting of the insulin-like growth factor 2 receptor","volume":"205","author":"Xihua","year":"2019","journal-title":"Transl Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.736677","article-title":"Analysis of miRNAs profiles in serum of patients with steatosis and steatohepatitis","volume":"9","author":"Vulf","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0810550106","article-title":"miR-375 maintains normal pancreatic alpha- and beta-cell mass","volume":"106","author":"Poy","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.14000","article-title":"MiRNome profiling of circulating extracellular vesicles in patients with chronic hepatitis D undergoing pegylated interferon alpha treatment","volume":"31","author":"Caviglia","year":"2024","journal-title":"J Viral Hepat"},{"key":"B75","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1042\/BSR20181722","article-title":"LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a\/PPARgamma axis in non-alcoholic fatty liver disease","volume":"39","author":"Liu","year":"2019","journal-title":"Biosci Rep"},{"key":"B76","doi-asserted-by":"publisher","first-page":"e120304","DOI":"10.1172\/jci.insight.120304","article-title":"Elevated hepatic expression of H19 long noncoding RNA contributes to diabetic hyperglycemia","volume":"3","author":"Zhang","year":"2018","journal-title":"JCI Insight"},{"key":"B77","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13098-021-00719-3","article-title":"Diagnostic significance of serum lncRNA HOTAIR and its predictive value for the development of chronic complications in patients with type 2 diabetes mellitus","volume":"13","author":"Wang","year":"2021","journal-title":"Diabetol Metab Syndr"},{"key":"B78","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3390\/biom14030277","article-title":"Extracellular vesicles as delivery vehicles for non-coding RNAs: potential biomarkers for chronic liver diseases","volume":"14","author":"Ferro","year":"2024","journal-title":"Biomolecules"},{"key":"B79","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.omtn.2019.08.002","article-title":"Exercise Reduces Insulin Resistance in Type 2 Diabetes Mellitus via Mediating the lncRNA MALAT1\/MicroRNA-382-3p\/Resistin Axis","volume":"18","author":"Liu","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.734643","article-title":"Long non-coding RNA MALAT1: A key player in liver diseases","volume":"8","author":"Lu","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.2174\/1381612828666220428093207","article-title":"NEAT1: A novel long non-coding RNA involved in mediating type 2 diabetes and its various complications","volume":"28","author":"Jia","year":"2022","journal-title":"Curr Pharm Des"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-020-03810-x","article-title":"Upregulation of long non-coding RNA MEG3 in type 2 diabetes mellitus complicated with vascular disease: a case-control study","volume":"473","author":"Chang","year":"2020","journal-title":"Mol Cell Biochem"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.metabol.2019.01.018","article-title":"LncRNA MEG3 functions as a ceRNA in regulating hepatic lipogenesis by competitively binding to miR-21 with LRP6","volume":"94","author":"Huang","year":"2019","journal-title":"Metabolism"},{"key":"B84","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/metabo14010012","article-title":"Lipid metabolism in metabolic-associated steatotic liver disease (MASLD)","volume":"14","author":"Syed-Abdul","year":"2023","journal-title":"Metabolites"},{"key":"B85","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41573-021-00367-2","article-title":"Lipogenesis inhibitors: therapeutic opportunities and challenges","volume":"21","author":"Batchuluun","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B86","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.cmet.2022.05.004","article-title":"Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia","volume":"34","author":"Morrow","year":"2022","journal-title":"Cell Metab"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.06.020","article-title":"Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression","volume":"2","author":"Ventura","year":"2015","journal-title":"EBioMedicine"},{"key":"B88","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1681\/ASN.2021050723","article-title":"DGAT2 inhibition potentiates lipid droplet formation to reduce cytotoxicity in APOL1 kidney risk variants","volume":"33","author":"Chun","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1210\/er.2018-00064","article-title":"Molecular actions of PPARalpha in lipid metabolism and inflammation","volume":"39","author":"Bougarne","year":"2018","journal-title":"Endocr Rev"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s44161-024-00448-6","article-title":"Kupffer cells dictate hepatic responses to the atherogenic dyslipidemic insult","volume":"3","author":"Di Nunzio","year":"2024","journal-title":"Nat Cardiovasc Res"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00391.2009","article-title":"Kupffer cell activation is a causal factor for hepatic insulin resistance","volume":"298","author":"Lanthier","year":"2010","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2014.01.156","article-title":"Lack of interleukin-1alpha in Kupffer cells attenuates liver inflammation and expression of inflammatory cytokines in hypercholesterolaemic mice","volume":"46","author":"Olteanu","year":"2014","journal-title":"Dig Liver Dis"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.01.048","article-title":"Lack of interleukin-1alpha or interleukin-1beta inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice","volume":"55","author":"Kamari","year":"2011","journal-title":"J Hepatol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/hep.30990","article-title":"Yes-associated protein in kupffer cells enhances the production of proinflammatory cytokines and promotes the development of nonalcoholic steatohepatitis","volume":"72","author":"Song","year":"2020","journal-title":"Hepatology"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.04.019","article-title":"Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis","volume":"47","author":"Rivera","year":"2007","journal-title":"J Hepatol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3390\/antiox9121279","article-title":"Molecular mechanisms that link oxidative stress, inflammation, and fibrosis in the liver","volume":"9","author":"Ramos-Tovar","year":"2020","journal-title":"Antioxid (Basel)"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1183808","article-title":"Mechanical homeostasis imbalance in hepatic stellate cells activation and hepatic fibrosis","volume":"10","author":"Zhao","year":"2023","journal-title":"Front Mol Biosci"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3390\/cells8111419","article-title":"TGF-beta in hepatic stellate cell activation and liver fibrogenesis-updated 2019","volume":"8","author":"Dewidar","year":"2019","journal-title":"Cells"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.04.011","article-title":"The Hippo pathway effector YAP controls mouse hepatic stellate cell activation","volume":"63","author":"Mannaerts","year":"2015","journal-title":"J Hepatol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.10.044","article-title":"Multi-modal analysis of human hepatic stellate cells identifies novel therapeutic targets for metabolic dysfunction-associated steatotic liver disease","volume":"82","author":"Kim","year":"2025","journal-title":"J Hepatol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.cmet.2024.04.003","article-title":"TM7SF3 controls TEAD1 splicing to prevent MASH-induced liver fibrosis","volume":"36","author":"Isaac","year":"2024","journal-title":"Cell Metab"},{"key":"B102","doi-asserted-by":"publisher","first-page":"107469","DOI":"10.1016\/j.celrep.2020.03.033","article-title":"Dysfunction of persisting beta cells is a key feature of early type 2 diabetes pathogenesis","volume":"31","author":"Cohrs","year":"2020","journal-title":"Cell Rep"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v14.i3.130","article-title":"Pancreatic beta-cell dysfunction in type 2 diabetes: Implications of inflammation and oxidative stress","volume":"14","author":"Dludla","year":"2023","journal-title":"World J Diabetes"},{"key":"B104","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jare.2023.10.008","article-title":"beta-cell neogenesis: A rising star to rescue diabetes mellitus","volume":"62","author":"Niu","year":"2024","journal-title":"J Adv Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3390\/cimb46070453","article-title":"Targeting beta-cell plasticity: A promising approach for diabetes treatment","volume":"46","author":"Ghasemi Gojani","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"102242","DOI":"10.1016\/j.molmet.2025.102242","article-title":"DYRK1A inhibition restores pancreatic functions and improves glucose metabolism in a preclinical model of type 2 diabetes","volume":"101","author":"Bertrand","year":"2025","journal-title":"Mol Metab"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00658","article-title":"Development of kinase-selective, harmine-based DYRK1A inhibitors that induce pancreatic human beta-cell proliferation","volume":"61","author":"Kumar","year":"2018","journal-title":"J Med Chem"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00362","article-title":"Combined oral administration of GABA and DPP-4 inhibitor prevents beta cell damage and promotes beta cell regeneration in mice","volume":"8","author":"Liu","year":"2017","journal-title":"Front Pharmacol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"111755","DOI":"10.1016\/j.mce.2022.111755","article-title":"Combined therapy of GABA and sitagliptin prevents high-fat diet impairment of beta-cell function","volume":"559","author":"Wang","year":"2023","journal-title":"Mol Cell Endocrinol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fcdhc.2025.1579961","article-title":"GLP-1 receptor agonists and pancreatic beta cell apoptosis in diabetes mellitus: a systematic review and meta-analysis of preclinical studies","volume":"6","author":"Rea","year":"2025","journal-title":"Front Clin Diabetes Healthc"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.2337\/db09-0685","article-title":"Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB","volume":"58","author":"Cunha","year":"2009","journal-title":"Diabetes"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.2337\/db09-0063","article-title":"Glucagon-like peptide-1 protects beta-cells against apoptosis by increasing the activity of an IGF-2\/IGF-1 receptor autocrine loop","volume":"58","author":"Cornu","year":"2009","journal-title":"Diabetes"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i39.6522","article-title":"Acetyl-CoA carboxylase inhibitors in non-alcoholic steatohepatitis: Is there a benefit","volume":"27","author":"Neokosmidis","year":"2021","journal-title":"World J Gastroenterol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1101\/2023.07.05.547848","article-title":"Dual targeting of hepatocyte DGAT2 and stellate cell FASN alleviates nonalcoholic steatohepatitis in mice","author":"Yenilmez","year":"2023","journal-title":"bioRxiv"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.867940","article-title":"Hepatic stellate cell-immune interactions in NASH","volume":"13","author":"Carter","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.05.009","article-title":"Resmetirom for treatment of MASH","volume":"187","author":"Sookoian","year":"2024","journal-title":"Cell"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31622","article-title":"Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00979-1","article-title":"Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicenter, randomized, double-blind, placebo-controlled, phase 2 trial","volume":"406","author":"Loomba","year":"2025","journal-title":"Lancet"},{"key":"B120","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41392-022-01119-3","article-title":"Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver\/steatohepatitis (NAFL\/NASH)","volume":"7","author":"Xu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B121","doi-asserted-by":"publisher","first-page":"111688","DOI":"10.1016\/j.diabres.2024.111688","article-title":"MASLD\/MASH and type 2 diabetes: Two sides of the same coin? From single PPAR to pan-PPAR agonists","volume":"212","author":"Cooreman","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"B122","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicenter, double-blind, randomized, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"B125","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"key":"B127","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with glp-1 receptor agonists: A multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Martinez","year":"2022","journal-title":"J Clin Med"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.8.2460","article-title":"Therapeutic roles of peroxisome proliferator-activated receptor agonists","volume":"54","author":"Staels","year":"2005","journal-title":"Diabetes"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.02.004","article-title":"Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)","volume":"78","author":"Harrison","year":"2023","journal-title":"J Hepatol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"B133","doi-asserted-by":"publisher","first-page":"5055","DOI":"10.3390\/ijms20205055","article-title":"Exploration and development of PPAR modulators in health and disease: an update of clinical evidence","volume":"20","author":"Cheng","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-024-00051-1","article-title":"NASH field celebrates \u2018hurrah moment\u2019 with a first FDA drug approval for the liver disease","volume":"23","author":"Kingwell","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicenter, randomized, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"B136","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.07.014","article-title":"Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis","volume":"79","author":"Sanyal","year":"2023","journal-title":"J Hepatol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"B139","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/aps.2014.116","article-title":"Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis","volume":"36","author":"Jiao","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.601349","article-title":"FGF19 and FGF21 for the treatment of NASH-two sides of the same coin? Differential and overlapping effects of FGF19 and FGF21 from mice to human","volume":"11","author":"Henriksson","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01073-6","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicenter, randomized, double-blind, placebo-controlled, phase 2b trial","volume":"406","author":"Noureddin","year":"2025","journal-title":"Lancet"},{"key":"B142","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"key":"B143","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1574385","article-title":"Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective","volume":"16","author":"Zeng","year":"2025","journal-title":"Front Pharmacol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3390\/cells13191662","article-title":"Inflammatory trajectory of type 2 diabetes: novel opportunities for early and late treatment","volume":"13","author":"Pellegrini","year":"2024","journal-title":"Cells"},{"key":"B146","doi-asserted-by":"publisher","first-page":"e186425","DOI":"10.1172\/JCI186425","article-title":"Therapeutic horizons in metabolic dysfunction-associated steatohepatitis","volume":"135","author":"Newsome","year":"2025","journal-title":"J Clin Invest"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/s44222-023-00063-3","article-title":"Human disease models in drug development","volume":"1","author":"Loewa","year":"2023","journal-title":"Nat\u00a0Rev Bioeng"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-025-09980-7","article-title":"Targeted therapeutic strategies as alternative and sustainable treatment options for obesity-induced steatohepatitis","volume":"26","author":"Mabuda","year":"2025","journal-title":"Rev Endocr Metab Disord"},{"key":"B149","doi-asserted-by":"publisher","first-page":"100018","DOI":"10.1016\/j.pharmr.2024.100018","article-title":"Pharmacological treatment for metabolic dysfunction-associated steatotic liver disease and related disorders: Current and emerging therapeutic options","volume":"77","author":"Zhang","year":"2025","journal-title":"Pharmacol Rev"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1753393\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T05:28:11Z","timestamp":1768800491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1753393\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":149,"alternative-id":["10.3389\/fendo.2025.1753393"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1753393","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"article-number":"1753393"}}